ATE220100T1 - Mit gp11b/iiia reaktive humane antikörper - Google Patents
Mit gp11b/iiia reaktive humane antikörperInfo
- Publication number
- ATE220100T1 ATE220100T1 AT92924918T AT92924918T ATE220100T1 AT E220100 T1 ATE220100 T1 AT E220100T1 AT 92924918 T AT92924918 T AT 92924918T AT 92924918 T AT92924918 T AT 92924918T AT E220100 T1 ATE220100 T1 AT E220100T1
- Authority
- AT
- Austria
- Prior art keywords
- iiia
- gp11b
- human antibodies
- antibodies reactive
- gpiib
- Prior art date
Links
- 108060003951 Immunoglobulin Proteins 0.000 abstract 1
- 102100025306 Integrin alpha-IIb Human genes 0.000 abstract 1
- 101710149643 Integrin alpha-IIb Proteins 0.000 abstract 1
- 108020004511 Recombinant DNA Proteins 0.000 abstract 1
- 208000007536 Thrombosis Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 102000018358 immunoglobulin Human genes 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
- C07K16/2848—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta3-subunit-containing molecules, e.g. CD41, CD51, CD61
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/54—F(ab')2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Medicinal Chemistry (AREA)
- General Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- Plant Pathology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Physics & Mathematics (AREA)
- Diabetes (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US81211191A | 1991-12-20 | 1991-12-20 | |
| US89595292A | 1992-06-09 | 1992-06-09 | |
| US94415992A | 1992-09-11 | 1992-09-11 | |
| PCT/JP1992/001630 WO1993013133A1 (en) | 1991-12-20 | 1992-12-15 | HUMAN TYPE ANTIBODY REACTIVE WITH GPIIb/IIIa |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE220100T1 true ATE220100T1 (de) | 2002-07-15 |
Family
ID=27420074
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT92924918T ATE220100T1 (de) | 1991-12-20 | 1992-12-15 | Mit gp11b/iiia reaktive humane antikörper |
Country Status (10)
| Country | Link |
|---|---|
| EP (1) | EP0619324B1 (de) |
| JP (1) | JP2723671B2 (de) |
| KR (1) | KR100240159B1 (de) |
| AT (1) | ATE220100T1 (de) |
| AU (1) | AU3095892A (de) |
| CA (1) | CA2126182C (de) |
| DE (1) | DE69232669T2 (de) |
| ES (1) | ES2179824T3 (de) |
| MX (1) | MX9207459A (de) |
| WO (1) | WO1993013133A1 (de) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE69334156T2 (de) | 1992-11-16 | 2008-04-10 | Centocor, Inc. | Verfahren zur Reduzierung der Immunogenizität der variablen Regionen von Antikörpern |
| UA37249C2 (uk) * | 1993-11-05 | 2001-05-15 | Сентокор Інк. | Спосіб інгібування стенозу та/або рестенозу (варіанти), спосіб інгібування рестенозу після проведення операції на коронарній артерії у людини (варіанти), спосіб зниження ймовірності виникнення чи запобігання негострих ішемічних ускладнень при ангіопластиці у людини |
| US6074642A (en) | 1994-05-02 | 2000-06-13 | Alexion Pharmaceuticals, Inc. | Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis |
| EP0962467A4 (de) | 1996-09-26 | 2002-10-30 | Chugai Pharmaceutical Co Ltd | Antikörper gegen menschliches parathormon verwandten peptide |
| AU750021C (en) | 1997-05-15 | 2003-10-16 | Chugai Seiyaku Kabushiki Kaisha | Cachexia remedy |
| AU745965B2 (en) * | 1997-06-06 | 2002-04-11 | Asat Ag Applied Science & Technology | Anti-GPIIb/IIIa recombinant antibodies |
| EP1174148A4 (de) * | 1999-04-28 | 2005-05-04 | Yamanouchi Pharma Co Ltd | Parenterale medizinische zusammensetzungen enthaltend fragmente humanisierter monoklonaler antikörper und methode zur stabilisierung derselben |
| TWI255718B (en) | 1999-07-02 | 2006-06-01 | Chugai Pharmaceutical Co Ltd | Ameliorative agent for low vasopressin concentration |
| ATE420661T1 (de) | 2000-04-28 | 2009-01-15 | Chugai Pharmaceutical Co Ltd | Zellproliferation-inhibitoren |
| GB0302699D0 (en) * | 2003-02-06 | 2003-03-12 | Univ Bradford | Immunoglobulin |
| ES2776657T3 (es) | 2005-06-14 | 2020-07-31 | Amgen Inc | Formulaciones de proteínas autotamponantes |
| WO2018075818A1 (en) | 2016-10-21 | 2018-04-26 | Amgen Inc. | Pharmaceutical formulations and methods of making the same |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8607679D0 (en) * | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| NO873164L (no) * | 1986-07-30 | 1988-02-01 | Teijin Ltd | Muse-humane kimaere antistoffer. |
-
1992
- 1992-12-15 EP EP92924918A patent/EP0619324B1/de not_active Expired - Lifetime
- 1992-12-15 WO PCT/JP1992/001630 patent/WO1993013133A1/ja not_active Ceased
- 1992-12-15 AU AU30958/92A patent/AU3095892A/en not_active Abandoned
- 1992-12-15 CA CA002126182A patent/CA2126182C/en not_active Expired - Fee Related
- 1992-12-15 KR KR1019940702179A patent/KR100240159B1/ko not_active Expired - Fee Related
- 1992-12-15 AT AT92924918T patent/ATE220100T1/de not_active IP Right Cessation
- 1992-12-15 JP JP5509612A patent/JP2723671B2/ja not_active Expired - Lifetime
- 1992-12-15 DE DE69232669T patent/DE69232669T2/de not_active Expired - Fee Related
- 1992-12-15 ES ES92924918T patent/ES2179824T3/es not_active Expired - Lifetime
- 1992-12-18 MX MX9207459A patent/MX9207459A/es not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| KR940703859A (ko) | 1994-12-12 |
| EP0619324B1 (de) | 2002-07-03 |
| ES2179824T3 (es) | 2003-02-01 |
| WO1993013133A1 (en) | 1993-07-08 |
| MX9207459A (es) | 1994-03-31 |
| AU3095892A (en) | 1993-07-28 |
| DE69232669T2 (de) | 2003-02-27 |
| EP0619324A4 (en) | 1995-11-29 |
| KR100240159B1 (ko) | 2000-01-15 |
| CA2126182C (en) | 2001-07-17 |
| DE69232669D1 (de) | 2002-08-08 |
| JP2723671B2 (ja) | 1998-03-09 |
| CA2126182A1 (en) | 1993-07-08 |
| EP0619324A1 (de) | 1994-10-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2108048T3 (es) | Produccion y utilizacion de animales inferiores transgenicos capaces de producir anticuerpos heterologos. | |
| ATE81153T1 (de) | Expressionssystem zur herstellung von chimaeren monoklonalen antikoerpern. | |
| DE69634726D1 (de) | Menschliche ctla-8 und verwendung von ctla-8 ähnlichen proteinen | |
| DE69232669D1 (de) | Mit gp11b/iiia reaktive humane antikörper | |
| ATE174628T1 (de) | Expression rekombinanter fusionsproteine in attenuierten bakterien | |
| DK0502812T3 (da) | Rekombinante antistoffer, som er specifikke for en vækstfaktorreceptor | |
| ATE340590T1 (de) | Gegen menschliches interleukin-8 gerichteter, rekonstituierter menschlicher antikörper | |
| ATE167896T1 (de) | Aus mehreren domänen bestehende hämatopoese- stimulatoren | |
| FI895346A0 (fi) | Bindande proteiner. | |
| DE69024862D1 (de) | Modifiziertes, biologisch aktives Protein | |
| DK0407813T3 (da) | Oxidativ denaturering af proteinanalytter | |
| DE10299038I2 (de) | Pl{ttchen-spezifisches Chim{risches immunglobulin. | |
| NO175639C (no) | Peptid, antistoff oppnådd ved hjelp av peptidet, en fremgangsmåte for immunologisk bestemmelse av intakt prokollagen peptid (type III) og anvendelse av peptidet | |
| DK442888D0 (da) | Slaegtspecifikt listeria-antigen identificeret ved hjaelp af monoklone antistoffer | |
| DE59310073D1 (de) | Verfahren zur Inaktivierung von Viren in Präparationen von Proteinen | |
| DK329789D0 (da) | Monoklonalt antistof | |
| FI885025A0 (fi) | Koagulationshaemmande protein pp4-x, dess framstaellning och anvaendning. | |
| DE68918440D1 (de) | Verfahren zur transformation von menschlichen b-lymphocyten. | |
| ATE110786T1 (de) | Monoklonaler antikörper gegen exotoxin a von pseudomonas aeruginosa. | |
| EP0332421A3 (en) | Monoclonal antibodies recognizing human psti, hybridomas producing the same, and their preparation and use | |
| SU1692146A1 (ru) | Штамм гибридных культивируемых клеток животных mus musculus l. - продуцент моноклональных антител к 146 s-компоненту вируса ящура o |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |